A new study found that the natural alkaloids mitragynine and 7-hydroxymitragynine from Mitragyna speciosa showed stable binding and favorable drug-likeness as potential HER2 inhibitors in breast cancer.
Palbociclib revolutionizes HR+/HER2- breast cancer treatment, enhancing outcomes with endocrine therapies and promising new combinations for better patient care.
Research reveals that clinical stage significantly influences survival rates in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.